Is RPRX a Buy or a Sell? The Bull and Bear Case (2026)

The most optimistic published target on RPRX is $70.00, +14.2% from the $61.31 price as of August 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

The most pessimistic published target is $61.00, -0.5% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Royalty Pharma is worth if the risks below bite instead of the drivers above.

Concentration is the first thing to size. Vertex's cystic fibrosis franchise supplied 32% of total income and other revenues in the second quarter of 2026 and 33% across the half, and its $194 million of quarterly Royalty Receipts were flat year on year. That royalty is perpetual in contract but the company models a 2039 to 2041 duration on expected Alyftrek patent expiry. There is also an unresolved dispute with the payor: beginning in the second quarter of 2025 Royalty Pharma did not receive what it believes it is contractually owed on Alyftrek net sales and has commenced the contractual dispute resolution procedures, with any recovery recognised only if the matter resolves in its favour. Individual royalties can also go to zero. Ipsen and Eisai withdrew Tazverik across all indications in March 2026, producing a $69.4 million non-cash impairment and the gross write-off of a $548.3 million financial royalty asset. Promacta receipts fell 75% in the quarter on US generic entry and Imbruvica fell 17%, both real cash declines that the growers merely offset. Reported earnings swing on estimates rather than operations: the provision for changes in expected cash flows was a $268 million charge in the second quarter of 2026 against a $204 million benefit a year earlier, which is why net income attributable to the plc fell to $17.9 million and diluted EPS to $0.04. Leverage of $9.2 billion sits ahead of shareholders and drove $187.3 million of interest expense in the half. Tax is a live question too: the company records no income tax expense today, and it flags the UK's adoption of the Pillar Two 15% global minimum tax rules alongside its own statement that its tax position is not free from doubt.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding RPRX already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

8 analysts cover RPRX, with an average target of $64.75 (+5.6% against $61.31) and a split of 7 buy, 1 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the RPRX forecast and price target page.

• Revenue (TTM, GAAP): ~$2.54 billion of total income and other revenues for the twelve months to June 30, 2026, against $2,378 million in fiscal 2025, $2,264 million in 2024 and $2,355 million in 2023. GAAP quarterly income was $674 million in the second quarter of 2026, of which $638 million was income from financial royalty assets and $36 million other royalty income. The line is not a sales figure in the ordinary sense: it is the interest component of royalty collections, accreted under the effective interest method off sell-side consensus sales forecasts, so it moves when analysts revise the drugs Royalty Pharma has bought into.
• Portfolio Receipts (the operating measure): $3,254 million in 2025, up 16% from $2,801 million in 2024, and $1,698 million in the first half of 2026, up 8.4% from $1,566.8 million. Royalty Receipts, the sales-linked core, were $3,127 million in 2025 and $1,655 million in the first half of 2026 (up 13.4%). Guidance raised on August 5, 2026 puts full-year Portfolio Receipts at $3,400 million to $3,500 million, with Royalty Receipts growth of 7% to 10% and an assumed ~1% currency tailwind, excluding anything transacted after that date.
• Earnings and EPS: Diluted EPS of $1.86 on a trailing twelve-month basis, from net income attributable to Royalty Pharma plc; GAAP net income was $770.95 million in fiscal 2025 and $858.98 million in 2024. The quarterly path is erratic by design: first-half 2026 diluted EPS was $0.71 on $312.6 million attributable to the plc, but the second quarter alone was $0.04 after a $268 million provision for changes in expected cash flows. Consolidated net income of $549.7 million in the half was reduced by $237.2 million attributable to non-controlling interests before reaching Class A holders.
• Cash flow and Adjusted EBITDA: Net cash provided by operating activities was $1,447 million in the first half of 2026 against $960 million a year earlier, and $2,490 million for full-year 2025. Adjusted EBITDA, defined in the credit agreement as Portfolio Receipts less payments for operating and professional costs, was $736 million in the second quarter and roughly $3.2 billion trailing; Portfolio Cash Flow, after net interest, was $736 million in the quarter and $2,724 million in 2025. Payments for operating and professional costs ran at 4.8% of Portfolio Receipts in the quarter versus 8.9% for all of 2025.
• Balance sheet and capital returns: Cash and equivalents of $812 million at June 30, 2026 against total debt with principal value of $9.2 billion, with the $380 million term loan repaid at maturity in July. Financial royalty assets carried at $17.08 billion within $19.82 billion of total assets, and shareholders' equity of $9.79 billion including $2.95 billion of non-controlling interests. Capital returned in the half: $209 million of dividends and ~$95.6 million of buybacks (2.0 million Class A shares), with ~$1.7 billion left on the $3.0 billion authorisation. Accrued compensation liabilities were $713.2 million.
• Market pricing: Recently ~$61.31 per Class A share against a 52-week range of $34.08 to $62.13, for a market capitalisation of ~$35.25 billion. Share count as of July 31, 2026 was 445.28 million Class A plus 129.72 million Class B, and because Class B carries votes but essentially no economics in the plc (the paired RP Holdings Class B Interests exchange one-for-one into Class A), ~575 million is the economically relevant figure while basic EPS is struck on ~445 million. Trailing P/E of ~32.9 against a forward P/E near 11.4, dividend of $0.235 per quarter (~$0.94 annualised, ~1.5%), and enterprise value of roughly $43 billion, about 13.5 times trailing Adjusted EBITDA.

The ~14 times sales a screener prints comes from dividing a $35.25 billion market cap by $2.54 billion of GAAP revenue, which is the wrong denominator for this structure. Measured against the $3.4 billion to $3.5 billion of Portfolio Receipts guided for 2026, the same market cap is about 10 times, and enterprise value is roughly 13.5 times trailing Adjusted EBITDA. The gap between the trailing P/E near 33 and a forward P/E near 11 is the same effect seen from the earnings side, with non-cash provisions and impairments compressing reported profit while cash collections keep rising.

Rather than asking whether RPRX is a buy in the abstract, it tends to help to answer four questions:

• Thesis: do you believe the bull case above, and is it still true today?
• Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
• Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
• Overlap: check whether you already hold RPRX indirectly through an index or sector ETF before adding more.

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

• Bull case breaks if: Royalty Receipts are outrunning the headline receipts number stalls in the reported numbers rather than in the narrative around them.
• Bear case breaks if: concentration is the first thing to size fails to materialise over several reporting periods while the drivers keep compounding.
• Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the RPRX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about RPRX against your real portfolio and see your actual exposure before deciding.